Sanofi inks $358M Kiadis takeover to acquire NK-cell platform

Sanofi inks $358M Kiadis takeover to acquire NK-cell platform

Source: 
Fierce Biotech
snippet: 

Sanofi has struck a deal to buy Kiadis for €308 million ($358 million). The takeover will give Sanofi full control of an off-the-shelf natural killer (NK) cell platform it is already using to try to enhance its multiple myeloma drug Sarclisa.